Author of

• 17493

  +

  P2.02 - Poster Session with Presenters Present (ID 462)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Locally Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 17511

    +

    P2.02-018 - Chemoradiotherapy in Elderly Patients with Locally Advanced Non-Small Cell Lung Cancer (ID 5607)

    14:30 - 14:30  |  Author(s): A. Barroso
    • Abstract

    Background:
    The incidence of lung cancer increases with age and approximately 50% of non-small cell lung cancer (NSCLC) patients are over 70 years old. Combined modality therapy is standard of care for patients with unresectable locally advanced non-small cell lung cancer (NSCLC), however, despite the multitude of clinical trials performed, elderly patients have been under-represented in these studies. Objective: To investigate outcomes for elderly patients treated with chemoradiotherapy (CRT).
    
    Methods:
    Patients with locally advanced stage NSCLC admitted in a tertiary hospital, between 1th January 2014 and 31th may 2016, who received CRT were selected. Patients were divided in two groups by age (<70 vs. ≥70-years old). Clinical-demographic variables, overall survival (OS) and progression free survival (PFS) were compared between the two groups.
    
    Results:
    Fifty-one patients were included. The results are presented in the table:

    	<70years n=23(45,1%)	≥70years n=28(54,9%)	p
    Gender
    Male[n;(%)]	19(82.6)	26(92.9)	0.390
    Performance status (at diagnosis)[n;(%)]
    0	6(26.1)	10(35.7)	0.172
    1	16(69.6)	13(46.4)
    2	1(4.3)	5(17.9)
    Weight loss (at diagnosis)[n;(%)]
    0%	14(60.9)	16(57.1)	0.895
    5%	6(26.1)	7(25.0)
    10%	3(13.0)	5(17.9)
    Clinical stage[n;(%)]
    IIIA	10(43.5)	17(60.7)	0.070
    IIIB	13(56.5)	11(39.3)
    Comorbidities[n;(%)]
    Heart failure	-	4(14.8)	0.076
    Hypertension	7(30.4)	20(74.1)	0.002
    Dyslipidemia	5(21.7)	12(44.4)	0.091
    Chemotherapy regimen[n;(%)]
    Carboplatin	5(21.7)	20(71.4)	0.146
    Cisplatin	18(78.3)	8(28.6)
    CRT[n;(%)]
    Sequential	6(26.1)	11(39.3)	0.320
    Concurrent	17(73.9)	17(60.7)
    Second line treatment[n;(%)]
    No	16(69.6)	21(75.0)	0.320
    Yes	7(30.4)	7(25.0)

    Comparing with younger group the elderly group presented significant worse OS and longer PFS, although without statistical significance [respectively, median 7 vs. 12months (p=0.006) and median 11.5 vs. 8months (p=0.687)]. Elderly patients with higher PS presented worse survival (p=0.045). Patients submitted to a chemotherapy regimen with cisplatin presented better OS and PFS in both groups, although only statistical significant for the OS in patients under 70 years (p=0.023). There was no influence of other variables on OS and PFS.
    
    Conclusion:
    In our sample age was an important prognostic factor in patients submitted to CRT but other factors, as PS, also can influence prognosis. In both groups patients treated with cisplatin presented superior OS but less patients above 70 years received this treatment. Elderly patients could be considered for CRT treatment but each case should be analysed individually. More studies are needed to guide treatment in this population.